



HAL
open science

Blisters and Loss of Epidermis in Patients With Lupus Erythematosus

Carine Merklen-Djafri, Didier Bessis, Camille Francès, Nicolas Poulalhon,
Sebastien Debarbieux, Nadège Cordel, Dan Lipsker

► **To cite this version:**

Carine Merklen-Djafri, Didier Bessis, Camille Francès, Nicolas Poulalhon, Sebastien Debarbieux, et al.. Blisters and Loss of Epidermis in Patients With Lupus Erythematosus. *Medicine*, 2015, 94 (46), pp.e2102. 10.1097/MD.0000000000002102. hal-01990795

HAL Id: hal-01990795

<https://hal.umontpellier.fr/hal-01990795>

Submitted on 23 Jan 2019

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Blisters and Loss of Epidermis in Patients With Lupus Erythematosus

A Clinicopathological Study of 22 Patients

Carine Merklen-Djafri, MD, Didier Bessis, MD, Camille Frances, MD, PhD, Nicolas Poulalhon, MD, Sébastien Debarbieux, MD, Nadège Cordel, MD, and Dan Lipsker, MD, PhD

Abstract: The nosology of bullous lesions or equivalents (vesicles, erosions, and crusts) in patients with lupus erythematosus (LE) is rarely addressed.

The primary aim of this study was to draw up a precise phenotypic inventory of such skin lesions; the secondary objective was to assess a potential relationship between the different types of loss of epidermis and extracutaneous lupus manifestations.

We conducted a retrospective multicenter study including 22 patients with definite LE and bullous lesions or equivalents. All biopsies were reviewed. Patients were recruited in the dermatology departments of 6 centers. Patients were included if they met the diagnosis of systemic LE according to American College of Rheumatology and/or Systemic Lupus International Collaborating Clinics criteria or diagnosis of cutaneous LE based on classic clinical criteria and/or histological ascertainment of LE. Patients were recruited through clinician's memory and photographic collections.

Three clinico-pathological patterns could be individualized. First, toxic epidermal necrolysis (TEN)-like, sheet-like, skin detachment; sun-exposure, mild mucosal involvement, and dermal mucin deposition allow differential diagnosis with classical Lyell syndrome. Second, vesiculo-bullae and/or crusting occurring on typical lesions of subacute cutaneous lupus erythematosus or chronic cutaneous lupus erythematosus. Third, tense vesicles and/or blisters with an underlying neutrophilic dermatosis and a usual response to dapsone.

A careful analysis of 22 LE patients with epidermal detachment reveals 2 main pathomechanisms: a classic LE interface dermatitis, which can be hyperacute and lead to TEN-like skin detachment; and a

neutrophilic dermatosis, with tense vesicles and/or blisters, including classic bullous LE.

(*Medicine* 94(46):e2102)

Abbreviations: ACLE = acute cutaneous lupus erythematosus, ACR = American College of Rheumatology, CCLE = chronic cutaneous lupus erythematosus, DEJ = dermal-epidermal junction, DH = dermatitis herpetiformis, EBA = epidermolysis bullosa acquisita, GVHD = graft versus host disease, LE = lupus erythematosus, SCLE = subacute cutaneous lupus erythematosus, TEN = toxic epidermal necrolysis.

INTRODUCTION

To date, the nosology of bullous lesions during lupus erythematosus (LE) remains poorly defined and often confusing.^{1,2} During the course of LE, bullous cutaneous lesions or equivalents, including vesicles, erosions, and/or crusts, can occur. Different pathogenetic mechanisms underlie the formation of such lesions, which can occur in heterogeneous groups of cutaneous lupus subtypes. However, their exact frequency in patients with LE is unknown, and most series devoted to cutaneous LE do not even mention them.³⁻⁸ If bullous systemic LE (SLE) has been the subject of numerous publications,⁹⁻¹⁵ bullous lesions or equivalents occurring on specific lesions of LE are less studied. Therefore, LE presenting as toxic epidermal necrolysis (TEN) was the subject of some publications,^{16-18,23} but it is probably still largely underdiagnosed. A classification of vesiculobullous lesions in LE was published in 2004 by Ting et al.¹⁸ He divided the various types of vesicular or bullous lesions that can be encountered in patients with LE into those that have or do not have LE-specific pathology.

The aim of this study was to clarify clinical, histological, and immunopathological features of bullous skin lesions or any other form of loss of epidermis in a series of 22 patients with LE. Patients with LE and any form of skin detachment—vesicles, bullae, erosions, and crusts—were included in order to make a precise phenotypic inventory and better assess the pathogenesis of such skin lesions. Pragmatically, these lesions will be grouped under the term “loss of epidermis.” Another objective was to identify whether a relationship exists between the different types of loss of epidermis and extracutaneous lupus manifestations.

METHODS

We conducted a descriptive retrospective multicenter study on 22 patients who had developed vesicles, bullae, erosions, or crusts in the course of LE. Under French law, this type of retrospective study does not need approval of an institutional

Editor: Ismael Maatouk.

Received: September 14, 2015; revised: October 16, 2015; accepted: October 28, 2015.

From the Faculté de Médecine, Université de Strasbourg; Clinique Dermatologique, Hôpitaux Universitaires de Strasbourg, Strasbourg (CM-D, DL); Faculté de Médecine, Université de Montpellier; Département de Dermatologie, Hôpital Saint Eloi, CHRU Montpellier, Montpellier (DB); Faculté de Médecine, Université Pierre-et-Marie-Curie Paris-VI, Service de Dermatologie Hôpital Tenon, Paris (CF); Faculté de Médecine, Université Claude Bernard Lyon 1, Service de Dermatologie, CHU Lyon Sud, Pierre-Bénite (NP, SD); and Service de Dermatologie-Médecine interne, CHU de Pointe-à-Pitre, Pointe-à-Pitre, Guadeloupe, (NC) France.

Correspondence: Dan Lipsker, Department of Dermatology, 1 place de l'Hôpital, 67000 Strasbourg, France (e-mail: dan.lipsker@chru-strasbourg.fr).

The Study Group of Systemic Diseases in Dermatology (EMSED: Etude des Maladies Systémiques en Dermatologie): Didier BESSIS, Nadège CORDEL, Camille FRANCES, Dan LIPSKER

The authors have no funding and conflicts of interest to disclose.

Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.

This is an open access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0, where it is permissible to download, share and reproduce the work in any medium, provided it is properly cited. The work cannot be changed in any way or used commercially.

ISSN: 0025-7974

DOI: 10.1097/MD.0000000000002102

review board. Patients were recruited in the dermatology departments of 2 secondary referral centers (Pointe-à-Pitre and Colmar) and 4 tertiary referral centers (Lyon, Montpellier, Paris, and Strasbourg) in France.

Patients were included if they met the following criteria:

- (1) Diagnosis of SLE according to American College of Rheumatology (ACR) and/or Systemic Lupus International Collaborating Clinics (SLICC) criteria or diagnosis of cutaneous LE based on classic clinical criteria and/or histological ascertainment of LE.
- (2) Loss of epidermis as a direct consequence of LE except for those lesions resulting from a lupus-related thrombotic vasculopathy or the presence of antiphospholipid antibodies or porphyria cutanea tarda.

Patients' recruitment was based on clinicians' memory and/or review of photographic collections (from 1985 to 2012). In all patients, medical records were reviewed and relevant clinical data including age, sex, duration, distribution and morphology of skin lesions, history of LE, serologic data, medications at the time of diagnosis, and response to treatment were recorded. All biopsies were reviewed by 2 of us (CM-D and DL). Mean duration of follow-up time was 5 years (2 months–25 years).

RESULTS

The files of 22 patients with loss of epidermis in the course of LE were reviewed. Two of them have been reported previously.^{19,20}

Clinical Findings

There were 16 women and 6 men. The average age for the onset of bullous or equivalent lesions was 52 years (7–79 years). The average age for the diagnosis of LE was 46 years. Bullous or equivalent lesions were the presenting manifestation of LE in 9 of 22 patients. The individual lesions were flaccid blisters or vesicles, sheet-like detachment, erosions, crusts, tense blisters, or vesicles. Lesions were photodistributed in 7 of 22 patients. Mucous membrane involvement was seen in 7 of 22 patients (genital in 2 patients, oral in 6 patients, and conjunctival in 1 patient). Concomitant-specific LE lesions of either acute, subacute, or chronic type were seen in 14 patients. Thirteen of 22 patients had 4 or >4 ACR criteria and 17 had 4 or >4 SLICC criteria.

Histopathological Findings

The histopathological findings of these lesions were highly variable. Besides the typical lupus interface dermatitis, some patients had extensive epidermal necrosis, whereas others had a neutrophilic dermatosis. Fourteen of 22 patients had a typical interface dermatitis with varying degrees of vacuolar changes, basal cell necrosis, basement membrane thickening, epidermal atrophy, superficial and deep dermal lymphocytic infiltrate, and mucin deposition. Extensive necrosis of the epidermis was observed in 5 of 22 patients. Eight of 22 patients had a neutrophilic dermal infiltrate, forming papillary microabscesses in some patients, occupying all the upper dermis or even the whole dermis with important interstitial spreading in other patients, sometimes with leucocytoclasia but without vasculitis. Thus, patients could be grouped into 3 profiles shown in Table 1, Table 2, and Table 3.

Group 1: TEN-Like LE

In the first group composed of 5 patients, the following common clinical features were observed: flaccid blisters (4/5), sheet-like detachments (4/5), erosions (5/5), and tense blisters (1/5). There was mild vulvar mucosal involvement in 1 patient and cheilitis in 2 of 5 patients. Lesions began on sun-exposed skin or were photodistributed in 4 of 5 patients. Only one of them had a history of previous subacute cutaneous lupus erythematosus (SCLE). Three of 5 patients met ACR criteria for SLE, and 4 of them met SLICC criteria. In 2 of 5 patients, no triggering drug was found. In 3 of 5 patients, sheet-like detachments were preceded by drug intake. These drugs were not classically associated with TEN (diacerein, sulbutiamin, docetaxel, cyclophosphamide, and trastuzumab) (Table 1, Figure 1).

At histological examination, there was an extensive epidermal necrosis in 4 of 5 patients. Basal vacuolization and isolated keratinocytes necrosis were seen in all patients and mucin deposition in 3 patients. Direct immunofluorescence revealed a granular fluorescence at dermal–epidermal junction (DEJ) in 2 of 5 patients, with IgG, IgM, and C3. These patients can be classified as having a TEN-like LE.

Group 2: Classic Cutaneous LE (Interface Dermatitis) With Loss of Epidermis

In the second group composed of 9 patients, the following common clinical features were observed: erosions (7/9), crusts (7/9), localized sheet-like detachment (1/9), tense bullae (2/9), and/or vesicles (1/9). These losses of epidermis arose on LE-specific lesions (SCLE in 8/9 and chronic cutaneous lupus erythematosus [CCLE] in 1/9). There was no mucosal involvement in 7 of 9 patients. Two had oral ulcerations. Lesions were photodistributed in 3 of 9 patients. Five of them had a history of cutaneous LE. Three patients of 9 met ACR criteria for SLE, and 5 of 9 met SLICC criteria (Table 2, Figure 2).

At histopathological examination, there was epidermal atrophy (7/9), isolated keratinocyte necrosis (9/9) or extensive epidermal necrosis (2/9), vacuolization of basal keratinocytes (9/9), and dermo-epidermal detachment (1/9). A lymphocytic infiltrate was present. It could be lichenoid and/or distributed around the vessels or appendages. Mucin deposition was seen in 4 of 8 patients. Direct immunofluorescence revealed a granular fluorescence at DEJ in 2 of 8 patients and a dust-like particle pattern in 2 of 8 patients. These patients can be classified as having a vesiculobullous annular SCLE or CCLE.

Group 3: Neutrophilic Bullous LE

In the third group composed of 8 patients, the following common clinical features were observed: tense vesicles and bullae (2/8), tense bullae (5/8), crusts (3/8), and/or erosions (2/8). Three of 8 patients presented mucosal involvement (isolated oral ulcerations in 2 of 8 patients and oral, genital, and conjunctival ulcerations in 1 of 8 patients). Lesions were not photodistributed. They occurred on normal appearing or inflammatory skin. Only 2 patients had concomitant LE-specific lesions (acute cutaneous lupus erythematosus [ACLE] or CCLE). Four of 8 patients had no history of cutaneous LE. Seven of 8 patients met ACR criteria for SLE and all of them had at least 4 SLICC criteria. Among these 8 patients, 3 had concomitant glomerulonephritis (Table 3, Figure 3).

Histological examination showed either dermal–epidermal cleavage (in 7 of 8 patients) or superficial dermal edema (in 1 patient). A neutrophilic infiltrate was constant, with a

TABLE 1. Toxic Epidermal Necrolysis-Like Cutaneous Lupus Erythematosus

Patients	1	2	3	4	5
Age, sex	66, female	46, female	62, male	78, female	70, female
Type of loss of epidermis	Flaccid vesicles and bullae, erosions	Flaccid bullae, sheet-like detachment	Sheet-like detachment	Flaccid bullae, sheet-like detachment	Flaccid and tense bullae, sheet-like detachment
Mucous membrane involvement	No	No	No	No	Yes (vulvar)
Photodistribution	Yes	Yes	No	Yes	Yes
LE-specific lesions	No	Previous SCLE	Concomitant SCLE	Concomitant ACLE	Concomitant ACLE
ACR criteria	4 (photosensitivity, oral ulcerations, hematologic disorder, ANA)	2 (photosensitivity, ANA)	4 (photosensitivity, hematologic disorder, ANA, serositis)	4 (photosensitivity, hematologic disorder, proteinuria)	3 (photosensitivity, "malar rash," ANA)
SLICC criteria	7: 4 (clinical) + 3 (immunologic)	4: 1 (clinical) + 3 (immunologic)	4: 3 (clinical) + 1 (immunologic)	6: 4 (clinical) + 2 (immunologic)	2: 1 (clinical) + 1 (immunologic)
Visceral lupus erythematosus	—	—	—	—	—
Known lupus erythematosus	No	Yes	No	No	No
Epidermal atrophy	+	+	—	+	+
Epidermal necrosis	Extensive epidermal necrosis +++ and isolated keratinocytes necrosis	Intraepidermal bullae with necrosis of the blister roof and isolated keratinocytes necrosis +	Extensive epidermal necrosis ++ and isolated keratinocytes necrosis ++ (basal layer)	Extensive epidermal necrosis ++ and isolated keratinocytes necrosis	Focal epidermal necrosis and isolated keratinocytes necrosis ++ (basal layer and suprabasal layer)
Exocytosis	+ lymphocytes and PMN	—	+	+	+
DEJ	Vacuolization of basal keratinocytes +	Vacuolization of basal keratinocytes	Vacuolization of basal keratinocytes or dermal-epidermal separation	Vacuolization of basal keratinocytes	Vacuolization of basal keratinocytes ++++
Pigment incontinence	+	+	—	—	+
Dermal lymphocytic infiltrate	+ (perivascular)	+ (perivascular)	+ (perivascular)	+ (perivascular)	+ (perivascular)
Neutrophilic infiltrate	Perivascular +++ and interstitial ++	—	++ (dermal and in the epidermal necrotic area)	—	—
Mucin	+	+	—	+	—
DIF	Granular fluorescence at DEJ (IgG and C3); fluorescence of the dermal vessel walls (C3)	Granular fluorescence at DEJ (IgG, IgM, and C3)	Negative	Negative	Cytopid bodies (IgG, IgA, and C3)
Antinuclear antibodies	1:1280	1:640	1:1280	1:1280	1:1600
Anti-Ro antibodies	Negative	Positive	Positive	Positive	Positive
Complement	Lowered (CH50, C3 and C4)	Lowered (C3 and C4)	Normal	Lowered (C3 and C4)	Normal
Triggering factor	—	—	Drug? (diacerein)	Drug? (sulbutiamin)	Drugs? (docetaxel, cyclophosphamide, trastuzumab)

ACLE = acute cutaneous lupus erythematosus, ACR = American College of Rheumatology, ANA = antinuclear antibodies, DEJ = dermal-epidermal junction, DIF = direct immunofluorescence, LE = lupus erythematosus, PMN = polymorphonuclear, SCLE = subacute cutaneous lupus erythematosus, SLICC = Systemic Lupus International Collaborating Clinics.

TABLE 2. Vesiculobullous Annular Subacute Cutaneous Lupus Erythematosus and Vesiculobullous Chronic Cutaneous Lupus Erythematosus

Patients	6	7	8	9	10	11	12	13	14
Age, sex	57, female	72, female	60, male	79, female	73, female	67, female	41, male	45, male	47, male
Type of loss of epidermis	Erosions, crusts	Erosions, crusts, sheet-like detachment	Erosions	Erosions and crusts	Erosions and crusts	Tense bullae and crusts	Vesicles and crusts	Tense bullae and erosions	Erosions and crusts
Mucous membrane involvement	No	No	No	Yes (oral ulcerations)	No	Yes (oral ulceration)	No	No	No
Photodistribution	No	No	No	Yes	Yes	No	Yes	No	Yes
LE-specific lesions	Concomitant and previous SCLE, previous CCLE	Concomitant SCLE	Concomitant SCLE	Concomitant and previous SCLE	Concomitant SCLE and previous CCLE	Concomitant SCLE	Concomitant SCLE	Concomitant and previous CCLE and SCLE	Previous and concomitant CCLE
ACR criteria	5 (odisoid rash), hematologic disorder, renal disorder, nonerosive arthritis, ANA)	3 (malar rash, hematologic disorder, ANA)	1 (hematologic disorder)	5 (hematologic disorder, oral ulcerations, nonerosive arthritis, ANA, photosensitivity)	1 (photosensitivity)	3 (oral ulcerations, nonerosive arthritis, ANA)	2 (malar rash, ANA)	5 ("discoid rash," ANA, anti-SM antibodies, renal disorder, nonerosive arthritis)	3 (photosensitivity, "odisoid rash," ANA)
SLICC criteria	7; 5 (clinical) + 2 (immunologic)	5; 3 (clinical) + 2 (immunologic)	2; 1 (clinical) + 1 (immunologic)	6; 5 (clinical) + 1 (immunologic)	3; 3 (clinical) + 0 (immunologic)	5; 3 (clinical) + 2 (immunologic)	3; 1 (clinical) + 2 (immunologic)	6; 4 (clinical) + 2 (immunologic)	3; 1 (clinical) + 2 (immunologic)
Visceral lupus erythematosus	Pulmonary involvement (previous), renal disorder (previous and concomitant)	—	—	—	—	—	—	Renal disorder (previous)	—
Known lupus erythematosus	Yes	No	No	Yes	Yes	No	No	Yes	Yes
Epidermal atrophy	++	++	—	++	++	++	+	—	++
Epidermal necrosis	Isolated keratinocytes necrosis +	Extensive epidermal necrosis +++ and isolated keratinocytes necrosis +	Isolated keratinocytes necrosis +++	Isolated keratinocytes necrosis +	Isolated keratinocytes necrosis +	Isolated keratinocytes necrosis +	Isolated keratinocytes necrosis ++	Extensive epidermal necrosis +++ and isolated keratinocytes necrosis +	Isolated keratinocytes necrosis ++
Exocytosis	+	—	—	+	—	—	++	—	—
DEJ	Vacuolization of basal keratinocytes ++	Vacuolization of basal keratinocyte +	Vacuolization of basal keratinocytes +	Vacuolization of basal keratinocytes +++	Vacuolization of basal keratinocytes +++	Bullae; vacuolization of basal keratinocytes ++	Vacuolization of basal keratinocytes +++	Vacuolization of basal keratinocytes +	Vacuolization of basal keratinocytes +++
Pigment incontinence	—	—	—	+	+++	++	+	—	+
Dermal lymphocytic infiltrate	+ (perivascular)	+ (perivascular)	++ (periapendageal)	++ lichenoid and perivascular	+++ deep and superficial)	++ (perivascular and in the bullous cavity)	++ (perivascular, periappendageal, margination along the DEJ)	+	++ lichenoid and perivascular
Neutrophilic infiltrate	Moderate	—	—	—	—	—	—	—	—
Mucin	—	—	+	+++	—	+++	—	—	++
DIF	Negative	Negative	Negative	Negative	microgranular fluorescence at DEJ (IgG)	Dust-like particles at DEJ (IgG and C3)	microgranular fluorescence at DEJ (C3 and IgM)	Negative	Dust-like particles (IgM and C3), continuous granular fluorescence at DEJ (IgM)
Antinuclear antibodies	1:1280	1:500	1:160	1:1280	—	1:1280	1:640	1:640	1:640
Anti-Ro antibodies	Positive	Positive	Positive	—	—	Positive	Positive	Negative	Positive
Complement	Lowered (CH50 and C3)	Lowered (CH50 and C3)	Normal	Normal	NA	Lowered (CH50, C3 and C4)	Lowered (C3)	Lowered (CH50)	Lowered (C1q deficiency)
Triggering factor	—	Drugs? (alprazolam, amoxicillin-clavulanic acid)	Drugs? (ansoprazole, ezetimibe, ranitidine)	—	Drug? (anastrozole)	Drug? (cyclophosphamide, vincristine, epirubicin)	Photocopy	—	Photocopy

ACR = American College of Rheumatology, ANA = antinuclear antibodies, CCLE = chronic cutaneous lupus erythematosus, DEJ = dermal-epidermal junction, DIF = direct immunofluorescence, LE = lupus erythematosus, NA = not available, SCLC = subacute cutaneous lupus erythematosus, SLICC = Systemic Lupus International Collaborating Clinics.

TABLE 3. Bullous Neutrophilic Lupus Erythematosus

Patients	15	16	17	18	19	20	21	22
Age, sex	17, female	30, female	73, female	7, female child	40, male	33, female	33, female	42, female
Type of loss of epidermis	Tense vesicles and bullae	Tense bullae, crusts	Tense bullae, crusts	Tense bullae	Tense vesicles and bullae, erosions	Tense bullae	Tense bullae	Tense bullae, erosions, crusts
Mucous membrane involvement	—	—	—	Oral ulcerations	Bullae, erosions (oral, genital and conjunctival)	—	—	Oral ulcerations
Photodistribution	—	—	—	—	—	—	—	—
LE-specific lesions	Previous and concomitant ACLE, concomitant CCLE	No	No	No	No	Previous and concomitant ACLE	Previous ACLE	Previous ACLE
ACR criteria	6 (malar rash), «discoid rash», serositis ANA, nonerosive arthritis, renal disorder	4 (nonerosive arthritis, ANA, anti-dsDNA, mental disorders)	2 (hematological disorders, ANA)	6 (nonerosive arthritis, ANA, anti-dsDNA, hematological disorder, oral ulcerations, renal disorder)	4 (oral ulcerations, hematological disorder, ANA, anti-dsDNA)	4 (malar rash), nonerosive arthritis, ANA, anti-dsDNA)	6 (malar rash), ANA, anti-5m antibodies, anti-dsDNA, nonerosive arthritis, renal disorder)	4 (malar rash), nonerosive arthritis, ANA, anti-dsDNA)
SLICC	8: 5 (clinical) + 3 (immunologic)	5: 2 (clinical) + 3 (immunologic)	5: 3 (clinical) + 2 (immunologic)	8: 5 (clinical) + 3 (immunologic)	5: 3 (clinical) + 2 (immunologic)	4: 2 (clinical) + 2 (immunologic)	7: 3 (clinical) + 4 (immunologic)	7: 3 (clinical) + 4 (immunologic)
Visceral lupus erythematosus	Renal disorder (concomitant), serositis (previous)	Neuropsychiatric disorder?	—	Renal disorder (concomitant)	—	—	Renal disorder (concomitant)	—
Known lupus erythematosus	Yes	Yes	No	No	No	Yes	Yes	Yes
Epidermal atrophy	—	—	—	—	—	—	—	—
Epidermal necrosis	—	Isolated keratinocytes necrosis +	Isolated keratinocytes necrosis +	—	—	—	—	—
Spongiosis	+	—	Bullous microdetachment (over a neutrophilic infiltrate)	Superficial dermal edema	Bullous detachment	Bullous detachment	Bullous detachment	Bullous detachment
DEJ	Bullous microdetachment (over a neutrophilic infiltrate)	Bullous detachment	Bullous microdetachment (over a neutrophilic infiltrate)	++	—	—	—	—
Pigment incontinence	+	—	+	—	—	—	—	—
Dermal lymphocytic infiltrate	+	—	++	++	+	—	—	—
Neutrophilic infiltrate	+++ (subepidermal band-like infiltrate)	Papillary abscesses	++ (papillary abscesses, perivascular)	+++ (entire dermis, intense leucocytoclasia without vasculitis)	+ (superficial dermis, mild leucocytoclasia)	+++ (papillary abscesses, perivascular, interstitial, intense leucocytoclasia without vasculitis)	+++ (papillary abscesses)	+++ (subepidermal band-like, leucocytoclasia without vasculitis)
Type IV collagen immunostaining	NA	NA	NA	NA	Type IV collagen attached to the blister base	NA	NA	NA
DIF	Linear fluorescence (IgM and C3) at DEJ	Granular and linear fluorescence (IgA, G, and M) and C3 at DEJ	Dust-like particles (Ig A et G)	Continuous microgranular fluorescence at DEJ (IgG, M, and A)	Linear fluorescence (IgG and A) and C3 at DEJ	Granular fluorescence (IgA, IgG, and IgM) at DEJ	Granular fluorescence (IgG, A, M, and C1q) at DEJ	Linear fluorescence (IgG and C3 at DEJ)
DIF on salt-split skin	Negative	NA	NA	NA	NA	NA	NA	NA
Patients	15	16	17	18	19	20	21	22
IIF split skin	NA	Dermal side	NA	NA	NA	NA	NA	NA
EM	NA	NA	NA	NA	NA	NA	U-serated pattern, cleavage beneath the lamina densa	NA
Immunoblotting	200 kD	290 kD	NA	NA	Type VII collagen	NA	NA	Negative
Antinuclear antibodies	1:1200	1:1600	1:1280	1:1280	1:2560	1:640	1:2000	1:500
Anti-Ro antibodies	Positive	Positive	Positive	Negative	Negative	Positive	Negative	Positive
Complement	Lowered (CH50, C3 and C4)	Lowered (CH50, C3 and C4)	Partial C4 deficiency	Lowered (CH50, C3 and C4)	NA	Normal	Lowered (CH50 and C4)	Normal

ACLE = subacute cutaneous lupus erythematosus, ACR = American College of Rheumatology, ANA = antinuclear antibodies, anti-dsDNA = anti-double stranded DNA antibodies, CCLE = chronic cutaneous lupus erythematosus, DEJ = dermal-epidermal junction, DIF = direct immunofluorescence, EM = electron microscopy, IIF = indirect immunofluorescence, LE = lupus erythematosus, NA = not available, SLICC = Systemic Lupus International Collaborating Clinics.




FIGURE 1. A case of TEN-like LE—Patient 1: (A) photodistributed erosions and crusts; (b) epidermal atrophy and vacuolization of the basal layer. TEN = toxic epidermal necrolysis.




FIGURE 2. Cases of classic cutaneous LE with loss of epidermis: (A) patient 11—annular plaques centered by a crust; (B) patient 11—epidermal atrophy and dermo-epidermal blister; cavity filled with lymphocytes; (C) patient 14—erosions and crust on sun exposed skin; depigmented scars and atrophy; (D) patient 14—epidermal atrophy, interface dermatitis with vacuolization, lichenoid lympho-histiocytic infiltrate and mucin deposition.




FIGURE 3. A case of neutrophilic bullous LE: patient 16—(A) tense blisters and crusts on inflammatory skin; (B) blisters and neutrophilic papillary microabscesses.

pattern of papillary microabscesses in 4 of 8 patients, a dense subepidermal infiltrate in 3 of 8 patients or involving the entire dermis in 1 patient. LE-specific lesions, namely interface dermatitis, were absent in all 8 cases. Direct immunofluorescence examination revealed granular or linear immunoglobulin and C3 deposition at the DEJ (7/8) or a dust-like particles pattern (1/8). By immunoblotting, a 290 kD antigen was found in 2 patients and a 200 kD antigen was found in 1 patient. Immunoblotting was negative in 1 patient and was not performed in the remaining 4 of the 8 patients. These patients can be classified as having a bullous neutrophilic LE.

DISCUSSION

We report a series of 22 patients with loss of epidermis in the course of LE. The study of these patients led to distinguish 2 different pathological mechanisms that are likely to induce “loss of epidermis.” In the first group, skin surface alterations are related to a lupus-typical interface dermatitis at varying levels of intensity, which, if carried to the extreme, may cause TEN-like lesions. In the second group, the formation of bullae is underlaid by a neutrophilic dermal infiltrate; this group includes patients with classic bullous LE. To the best of our knowledge, no study has so far specifically addressed skin surface alterations in patients with LE. As the entry point of this study was purely morphologic, it is therefore relevant bedside, also in regards to treatment. Indeed, the erosive variants of DLE or SCLE are treated with antimalarials. In case of TEN-like LE, patients are usually hospitalized. As drug induction is not exceptional, a careful history is mandatory and every suspected drug must be interrupted. Photoprotection and appropriate skin care are essential and antimalarials are indicated. Finally, dapsone is the drug of choice for the neutrophilic variant of LE.

Patients’ recruitment mode (clinicians’ memory and/or review of photographic collections) constitutes a limitation in this study. Some data are missing due to the retrospective nature of the study. Thus, though the methodology of this study does not allow to draw any conclusion about the frequency of the different clinicopathological entities that we report, we nevertheless estimate that it is representative of the different types of surface alterations that are encountered in daily practice. First, because only experienced dermatologists participated in this study, and thus skin surface alterations would not go unnoticed; second, because in most participating centers, photos are taken from all patients with LE, and the systematic study of the photos provided a representative spectrum of the different clinical findings.

LE-Specific Vesiculobullous Skin Disease

When the lupus-typical interface dermatitis is particularly intense and acute, it can lead to epidermal necrosis, as in the course of TEN.^{16,17,23} This variant still is often not recognized as being LE²¹ and misdiagnosed as TEN. Ting et al¹⁸ distinguished 3 forms of TEN-like LE: TEN-like ACLE, in which the sheet-like cleavage of skin changes evolves rapidly from a preexisting photodistributed confluent or patchy erythema reaction that would otherwise be typical of localized or generalized ACLE; TEN-like SCLE, in which the sheet-like cleavage of skin changes evolves from otherwise typical photodistributed nonscarring annular or papulosquamous SCLE, in association with anti-Ro/SS-A or La/SS-B autoantibody production; TEN occurring in SLE patients with no conventional LE-specific skin lesions.

The diagnosis of TEN-like LE was made in 5 patients. All of them presented with an extensive epidermal necrosis and interface dermatitis. The presence or absence of anti-Ro is an element allowing the classification into one of the categories according to Ting. Four of our 5 patients had anti-Ro antibodies. The small size of these 2 groups does not allow retaining this finding as a determining factor. Drawing a distinction between subgroups of TEN-like LE seems irrelevant because the clinical features are similar in the 3 forms (flaccid bullae, vesicles, and sheet-like detachment and erosions) as well as histological features. It seems more didactic to group these 3 forms of TEN-like LE under the term “TEN-like hyperacute LE.” This diagnosis should be considered in any patient with sheet-like detachment when a photodistribution is noted, when mucous membrane involvement is discrete or absent, when antinuclear antibodies are present, or when mucin deposition is found in the biopsy specimen, particularly in the absence of high-risk drug intake. This entity remains probably underdiagnosed, as real TEN can also occur in SLE patients.²² It is important, however, to consider LE as a potential cause of acute syndrome of pan-epidermolysis, as are drug-induced Lyell syndrome or some fulminant cases of acute graft-versus-host disease (GVHD). Three of the 5 patients reported here with TEN-like LE had 4 ACR criteria (and 4 of them had 4 or more SLICC criteria), but lacked significant manifestations of visceral LE. Intravenous immunoglobulin therapy has been reported to be useful in TEN-like LE as well as in TEN and acute GVHD.^{4,23} TNF inhibitors have recently been reported to improve outcome in patients with TEN.^{24–28} These drugs are known to potentially induce LE and it is so far recommended not to administer them to patients with SLE. If their efficacy in patients with TEN should be confirmed, their use in patients with TEN-like LE should be carefully addressed.¹⁷

We also show here that classical LE lesions can evolve into “loss of epidermis,” through the same, but less acute mechanism. Histologically, there is a continuum between these different forms, supporting the notion of dermo-epidermal LE.²⁹ Although oral mucosa ulcerations are a classic manifestation of LE, and a diagnostic criterion in both ACR and SLICC criteria, our knowledge of loss of epidermis in classic LE lesions is poor. The relatively few patients with bullous evolution in classic LE variant as compared to TEN-like LE is probably biased. Physicians more easily remembered the patients with TEN-like LE who were always hospitalized, often for a few weeks, whereas the other patients are mainly seen on an outpatient basis, and attention is not always paid to crusting or peripheral vesiculation. Vesiculobullous annular SCLE and vesiculobullous CCLE were mainly characterized by erosions and crusts, and more rarely by bullae and vesicles. These losses of epidermis occurred at the active advancing edge of LE skin lesions or at the center of plaques.

Neutrophilic Vesiculobullous Skin Disease in Patients With LE

In the second group of patients, histopathological evaluation revealed a neutrophilic infiltrate, often mimicking dermatitis herpetiformis (DH). No lupus-characteristic interface dermatitis was present in cutaneous biopsy specimens. These LE-nonspecific vesiculobullous skin diseases do not occur as an extension of the interface dermatitis that is characteristic of LE-specific skin disease. In these cases, all the criteria for a defined autoimmune bullous dermatosis must be searched. When no autoimmune bullous dermatosis, such as DH, can be nosologically characterized, patients can be classified as having a neutrophilic bullous LE. In these cases, antibodies directed against collagen VII are usually detected, similarly to patients with epidermolysis bullosa acquisita (EBA), though the spectrum of autoantibodies found in these patients can probably be expanded.¹⁵

An explanation of the co-occurrence of these diseases could be that the interface dermatitis of classical LE could lead to the exposure of multiple epidermal and dermal antigens and cause a sensitization against these antigens. This sensitization would lead to the production of autoantibodies responsible for the induction of autoimmune bullous dermatoses, either defined (eg, EBA, DH, linear IgA dermatosis, P200 pemphigoid, or bullous pemphigoid), or not defined, when the antigen is not characterized or when the essential criteria for the definition of these dermatoses are not met. According to this hypothesis, bullous neutrophilic LE associated with the presence of antibodies directed against collagen VII, considered as “EBA-like vesiculobullous LE” in Ting’s classification, would be more an EBA secondary to LE than a subtype of neutrophilic LE.

Similarly, the individualization of “DH-like vesiculobullous LE” can be put into question. According to Ting, it is characterized by papillary microabscesses in combination with dense granular IgA and/or IgG deposits at the DEJ. It is necessary to differentiate the situation in which antitransglutaminase or antiendomysial antibodies are found, leading to the diagnosis of the DH, from the situation in which these antibodies are absent. In the latter case, in a patient with a history of LE (or in which LE is discovered on this occasion), the clinicopathological and immunopathological clinical picture can be considered as a bullous neutrophilic LE.

We could apply the same reasoning to other autoimmune bullous dermatoses such as linear IgA dermatosis or P200

pemphigoid occurring in patients with LE. But only half of the patients reported herein had previous LE lesions and thus this pathogenic hypothesis of exaggerated antigen exposition related to the interface dermatitis will not apply to them. We think that a subgroup of patients with LE is more prone to neutrophilic dermatoses in general including the different bullous variants.^{30,31} This is one more phenotypic dermatological presentation where the distinction between classic and neutrophilic LE is crucial.^{32–34} The correct recognition and diagnosis of the neutrophilic variant is critical, as treatment with dapsone will often allow complete control.

In patients with LE, we should definitely separate bullous lesions/loss of epidermis occurring in the setting of an interface dermatitis, from those occurring as a consequence of a neutrophilic dermatosis. The latter usually respond to dapsone, and can or cannot be immunopathologically characterized, whereas the former can either be a bullous variant of classic lupus lesions or, rarely, a life-threatening TEN-like acute dermatosis. Classic “bullous LE” is a dapsone-sensitive neutrophilic dermatosis, which probably encompasses different autoimmune bullous diseases. In the series reported here, the patients with neutrophilic bullous LE were those who had most frequently experienced associated significant renal involvement.

ACKNOWLEDGMENTS

The authors thank the following dermatologists and pathologists for having provided us the slides for the histologic data: Luc Durand, MD (Montpellier, France), Brigitte Balme, MD (Lyon, France), Stéphane Barete, MD (Paris, France), Jean Sarrouy, MD (Point-à-Pitre, France), Marie-Claire Tortel, MD (Colmar, France). All these physicians gave permission to be named.

REFERENCES

- Mebazaa A, El Euch D, Sellami M, et al. Lupus érythémateux systémique vésiculo-bulleux. *Rev Med Interne*. 2009;30:88–89.
- Itoi S, Tanemura A, Tsuji C, et al. A rare case of male bullous lupus erythematosus complicated with subsequent annular hypopigmentation. *Case Rep Dermatol*. 2014;6:91–97.
- Biazar C, Sigges J, Patsinakidis N, et al. Cutaneous lupus erythematosus: first multicenter database analysis of 1002 patients from the European Society of Cutaneous Lupus Erythematosus (EUSCLE). *Autoimmun Rev*. 2013;12:444–454.
- Vera-Recabarren MA, García-Carrasco M, Ramos-Casals M, et al. Comparative analysis of subacute cutaneous lupus erythematosus and chronic cutaneous lupus erythematosus: clinical and immunological study of 270 patients. *Br J Dermatol*. 2010;162:91–101.
- Vera-Recabarren MA, García-Carrasco M, Ramos-Casals M, et al. Cutaneous lupus erythematosus: clinical and immunological study of 308 patients stratified by gender. *Clin Exp Dermatol*. 2010;35:729–735.
- Walling HW, Sontheimer RD. Cutaneous Lupus Erythematosus. *Am J Clin Dermatol*. 2009;10:365–381.
- Callen JP. Chronic cutaneous lupus erythematosus. Clinical, laboratory, therapeutic, and prognostic examination of 62 patients. *Arch Dermatol*. 1982;118:412–416.
- Wallace DJ, Pistiner M, Nessim S, et al. Cutaneous lupus erythematosus without systemic lupus erythematosus: clinical and laboratory features. *Semin Arthritis Rheum*. 1992;21:221–226.
- Christodoulou G, Powell M, Nguyen VH, et al. An atypical case of bullous systemic lupus erythematosus in a 16-year-old boy. *Pediatr Dermatol*. 2014;31:e164–e166.

10. Ranario JS, Smith JL. Bullous lesions in a patient with systemic lupus erythematosus. *J Clin Aesthet Dermatol*. 2014;7:44–49.
11. Liu KL, Shen JL, Yang CS, et al. Bullous systemic lupus erythematosus in a child responding to dapsone. *Pediatr Dermatol*. 2014;31:e104–e106.
12. Maley A, Parker S. Bullous systemic lupus erythematosus in a patient with human immunodeficiency virus infection: a paradox of autoimmunity and immunodeficiency. *Dermatol Online J*. 2014;20:2014;9.
13. Contestable JJ, Edhegard KD, Meyerle JH. Bullous systemic lupus erythematosus: a review and update to diagnosis and treatment. *Am J Clin Dermatol*. 2014;15:517–524.
14. Lourenço DMR, Cunha Gomes R, Aikawa NE, et al. Childhood-onset bullous systemic lupus erythematosus. *Lupus*. 2014;23:1422–1425.
15. Chan LS, Lapiere JC, Chen M, et al. Bullous systemic lupus erythematosus with autoantibodies recognizing multiple skin basement membrane components, bullous pemphigoid antigen 1, laminin-5, laminin-6, and type VII collagen. *Arch Dermatol*. 1999;135:569–573.
16. Monga B, Ghosh S, Jain V. Toxic epidermal necrolysis-like rash of lupus: a dermatologist's dilemma. *Indian J Dermatol*. 2014;59:401–402.
17. Napolitano M, Giampetruzzi AR, Didona D, et al. Toxic epidermal necrolysis-like acute cutaneous lupus erythematosus successfully treated with a single dose of etanercept: report of three cases. *J Am Acad Dermatol*. 2013;69:e303–e305.
18. Ting W, Stone MS, Racila D, et al. Toxic epidermal necrolysis-like acute cutaneous lupus erythematosus and the spectrum of the acute syndrome of apoptotic pan-epidermolysis (ASAP): a case report, concept review and proposal for new classification of lupus erythematosus vesiculobullous skin lesions. *Lupus*. 2004;13:941–950.
19. Boisnic S, Frances C, Foldes C, et al. Manifestations cutanées rares au cours du lupus systémique: lésions bulleuses. *Ann Dermatol Venereol*. 1986;113:930–933.
20. Lipsker D, Hauptmann G. Cutaneous manifestations of complement deficiencies. *Lupus*. 2010;19:1096–1106.
21. Mahfouz A, Mahmoud AN, Ashfaq PA, et al. A case report of hydralazine-induced skin reaction: probable toxic epidermal necrolysis (TEN). *Am J Case Rep*. 2014;15:135–138.
22. Ziemer M, Kardaun Sh, Liss Y, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis in patients with lupus erythematosus: a descriptive study of 17 cases from a national registry and review of the literature. *Br J Dermatol*. 2012;166:575–600.
23. Mandelcorn R, Shear NH. Lupus-associated toxic epidermal necrolysis: a novel manifestation of lupus? *J Am Acad Dermatol*. 2003;48:525–529.
24. Gaitanis G, Spyridonos P, Patmanidis K, et al. Treatment of toxic epidermal necrolysis with the combination of infliximab and high-dose intravenous immunoglobulin. *Dermatology*. 2012;224:134–139.
25. Zárte-Correa LC, Carrillo-Gómez DC, Ramírez-Escobar AF, et al. Toxic epidermal necrolysis successfully treated with infliximab. *J Investig Allergol Clin Immunol*. 2013;23:61–63.
26. Hunger RE, Hunziker T, Buettiker U, et al. Rapid resolution of toxic epidermal necrolysis with anti-TNF-alpha treatment. *J Allergy Clin Immunol*. 2005;116:923–924.
27. Paradisi A, Abeni D, Bergamo F, et al. Etanercept therapy for toxic epidermal necrolysis. *J Am Acad Dermatol*. 2014;71:278–283.
28. Wojtkiewicz A, Wysocki M, Fortuna J, et al. Beneficial and rapid effect of infliximab on the course of toxic epidermal necrolysis. *Acta Derm Venereol*. 2008;88:420–421.
29. Lipsker D. Classification of specific cutaneous manifestations in patients with lupus erythematosus: a time for change? The concept of dermal lupus erythematosus. *Dermatology*. 2006;212:324–326.
30. Tobón GJ, Toro CE, Bravo JC, et al. Linear IgA bullous dermatosis associated with systemic lupus erythematosus: a case report. *Clin Rheumatol*. 2008;27:391–393.
31. Kurano TL, Lum CA, Izumi AK. The association of dermatitis herpetiformis and systemic lupus erythematosus. *J Am Acad Dermatol*. 2010;63:892–895.
32. Lipsker D, Saurat JH. Neutrophilic cutaneous lupus erythematosus. At the edge between innate and acquired immunity? *Dermatology*. 2008;216:283–286.
33. Kieffer C, Cribier B, Lipsker D. Neutrophilic urticarial dermatosis: a variant of neutrophilic urticaria strongly associated with systemic disease. Report of 9 new cases and review of the literature. *Medicine (Baltimore)*. 2009;88:23–31.
34. Gusdorf L, Bessis D, Lipsker D. Lupus erythematosus and neutrophilic urticarial dermatosis: a retrospective study of 7 patients. *Medicine (Baltimore)*. 2014;93:e351.